In recent years, immune checkpoints blockade therapy targeting the PD-1/PD-L1 axis has pushed tumor immunotherapy to a new revolutionary-like milestone and achieved surprising therapeutic effects in a variety of malignancies. This evidence concerns the gene PDCD1 and neoplasm.